What is Citius Oncology, Inc.'s interest paid?

Citius Oncology, Inc. (CTOR) reported interest paid of $14.46K in Q4 2025.

How has Citius Oncology, Inc.'s interest paid changed year-over-year?

Citius Oncology, Inc.'s interest paid decreased by 69.1% year-over-year, from $46.85K to $14.46K.

Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.

Arcus BiosciencesRCUS

$1.75M+600%

ImmunityBio, Inc.IBRX

$20.12M+29.0%

United TherapeuticsUTHR

$1.9M-64.8%

OmerosOMER

$5.57M-45.5%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s interest paid?: Citius Oncology, Inc. (CTOR) reported interest paid of $14.46K in Q4 2025.
How has Citius Oncology, Inc.'s interest paid changed year-over-year?: Citius Oncology, Inc.'s interest paid decreased by 69.1% year-over-year, from $46.85K to $14.46K.
What does interest paid mean?: Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.